Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248447 | 0.88 | MAPT (0.45) | KDM4EMAPTUSP2ALDH1A1GAA | |
| SCHEMBL7249987 | 0.86 | L3MBTL1 (0.47) | KCNH2KDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL2961524 | 0.82 | KCNH2 (0.54) | KCNH2KDM4EPOLBMAPTUSP2 | |
| SCHEMBL7034957 | 0.81 | KDM4E (0.46) | KCNH2KDM4EPOLBMAPTUSP2 | |
| SCHEMBL7250569 | 0.80 | MEN1 (0.47) | KCNH2KDM4EPOLBMAPTUSP2 | |
| SCHEMBL7251183 | 0.79 | NPC1 (0.42) | KDM4EMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL7245234 | 0.79 | ALDH1A1 (0.43) | KDM4EPOLBMAPTUSP2ALDH1A1 | |
| SCHEMBL5965991 | 0.79 | USP2 (0.44) | KCNH2KDM4EPOLBMAPTUSP2 | |
| SCHEMBL7248197 | 0.78 | KCNH2 (0.49) | KCNH2KDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL7244717 | 0.76 | MEN1 (0.51) | KCNH2KDM4EPOLBMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | KCNH2 2/4885KDM4E 3182/4885POLB 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.